NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition
High-performance phototheranostics with combined photothermal therapy and photoacoustic imaging have been considered promising approaches for efficient cancer diagnosis and treatment. However, developing phototheranostic materials with efficient photothermal conversion efficiency (PCE), especially over the second near-infrared window (NIR-II, 1000-1700 nm), remains challenging. Herein, we report an ultraefficient NIR-II-activated nanomedicine with phototheranostic and vaccination capability for highly efficient <i>in vivo</i> tumor elimination and metastasis inhibition. The NIR-II nanomedicine of a semiconducting biradical oligomer with a motor-flexible design was demonstrated with a record-breaking PCE of 87% upon NIR-II excitation. This nanomedicine inherently features extraordinary photothermal stability, good biocompatibility, and excellent photoacoustic performance, contributing to high-contrast photoacoustic imaging in living mice and high-performance photothermal elimination of tumors. Moreover, a whole-cell vaccine based on a NIR-II nanomedicine with NIR-II-activated performance was further designed to remotely activate the antitumor immunologic memory and effectively inhibit tumor occurrence and metastasis <i>in vivo</i>, with good biosafety. Thus, this work paves a new avenue for designing NIR-II active semiconducting biradical materials as a promising theranostics platform and further promotes the development of NIR-II nanomedicine for personalized cancer treatment.
Authors
- Yang Gao (ORCID: https://orcid.org/0000-0002-9068-9993)
- Shengliang Li (ORCID: https://orcid.org/0000-0002-3890-8482)
- Yingpeng Wan (ORCID: https://orcid.org/0000-0003-1432-9424)
- Lidai Wang (ORCID: https://orcid.org/0000-0003-3463-0740)
- Zhongming Huang (ORCID: https://orcid.org/0000-0001-5684-8746)
- Pengfei Wang (ORCID: https://orcid.org/0000-0002-9081-3683)
- Huan Chen (ORCID: https://orcid.org/0000-0003-0410-2533)
- Yachao Zhang (ORCID: https://orcid.org/0000-0002-1150-8745)
- Xiliang Li (ORCID: https://orcid.org/0000-0002-1542-7432)
- Weimin Liu (ORCID: https://orcid.org/0000-0001-7507-6032)
- Yu Wang (ORCID: https://orcid.org/0009-0005-0661-311X)
- Yujie Ma (ORCID: https://orcid.org/0009-0002-8401-054X)
Institutions
- City University of Hong Kong (HK)
- Chinese Academy of Sciences (CN)
- Soochow University (CN)
- Suzhou Institute of Biomedical Engineering and Technology (CN)
- Technical Institute of Physics and Chemistry (CN)
Publication Details
- Journal
- Acta Pharmaceutica Sinica B
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1016/j.apsb.2024.12.017
- Citations
- 6
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- City University of Hong Kong
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Science and Technology Program of Suzhou